Earlier, JMP Securities analyst Silvan Tuerkcan warned of an equity dilution. He stated, "We anticipate that Intellia Therapeutics is likely to seek additional equity financing in the form of a secondary offering in order to complete the development of its drug candidates, creating dilution risk for existing shareholders."